Antibiotic Innovation May Contribute to Slowing the Dissemination of Multiresistant Streptococcus pneumoniae: The Example of Ketolides
Open Access
- 7 May 2008
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 3 (5) , e2089
Abstract
Despite increasingly frequent bacterial resistance to antibiotics, antibacterial innovation is rare. Ketolides constitute one of the very few new antibiotic classes active against Streptococcus pneumoniae developed during the last 25 years. Their mechanism of action resembles that of macrolides, but they are unaffected by common resistance mechanisms. However, cross-resistance to ketolides has been observed in some macrolide-resistant strains. We examined how new antibiotic exposure may affect overall pneumococcal resistance patterns in the population. The aims of this study were to assess the potential dissemination of newly emerged resistances and to control the selection of strains already multiresistant to existing antimicrobials. We developed an age-structured population model for S. pneumoniae transmission in a human community exposed to heptavalent vaccine, and β-lactams, macrolides and ketolides. The dynamics of intra-individual selection of resistant strains under antibiotic exposure and interindividual transmission were simulated, with antibiotic-specific resistance mechanisms defining the path to co-resistances and cross-resistances, and parameters concerning the French situation. Results of this simulation study suggest that new antibiotic consumption could markedly slow the diffusion of multiresistant strains. Wider use was associated with slower progression of multiresistance. When ketolides were prescribed to all ages, resistance to them reached 10% after >15 years, while it took >40 years when they were prescribed only to adults. In the scenario according to which new antibiotics totally replaced former antimicrobials, the β-lactam resistance rate was limited at 70%. In a context of widespread vaccination and rational use of antibiotics, innovative antibiotic, prescribed to all age groups, may have an added impact on multiresistant-strain dissemination in the population.Keywords
This publication has 46 references indexed in Scilit:
- Emergence of a Multiresistant Serotype 19A Pneumococcal Strain Not Included in the 7-Valent Conjugate Vaccine as an Otopathogen in ChildrenJAMA, 2007
- Antimicrobial use in Europe and antimicrobial resistance in Streptococcus pneumoniaeEuropean Journal of Clinical Microbiology & Infectious Diseases, 2007
- Age- and Serogroup-Related Differences in Observed Durations of Nasopharyngeal Carriage of Penicillin-Resistant PneumococciJournal of Clinical Microbiology, 2007
- Fitness Costs of Fluoroquinolone Resistance in Streptococcus pneumoniaeAntimicrobial Agents and Chemotherapy, 2007
- Prevalence and Antibacterial Susceptibility of mef (A)-Positive Macrolide-Resistant Streptococcus pneumoniae over 4 Years (2000 to 2004) of the PROTEKT US StudyJournal of Clinical Microbiology, 2007
- Upgrading antibiotic use within a class: Tradeoff between resistance and treatment successProceedings of the National Academy of Sciences, 2006
- Antibody-Independent, Interleukin-17A-Mediated, Cross-Serotype Immunity to Pneumococci in Mice Immunized Intranasally with the Cell Wall PolysaccharideInfection and Immunity, 2006
- Pneumococcal Resistance in the Postvaccine EraThe Pediatric Infectious Disease Journal, 2006
- Telithromycin-resistantStreptococcus pneumoniaeEmerging Infectious Diseases, 2005
- Emergence and Spread ofStreptococcus pneumoniaewitherm(B) andmef(A) ResistanceEmerging Infectious Diseases, 2005